Law360, New York (January 23, 2012, 5:36 PM ET) -- The Federal Trade Commission has decided not to ask the U.S. Supreme Court to revive its suit accusing Lundbeck Inc. of illegally cornering the market on drugs used to treat heart defects in premature babies, the agency said Friday.
The decision will leave in place the Eighth Circuit's August ruling affirming the dismissal of the case — brought jointly with the state of Minnesota — after the court concluded that the FTC had failed to identify a relevant market. The panel ruled that the two drugs...
FTC To Drop Antitrust Suit Over Lundbeck Heart Defect Drug
To view the full article, take a free trial now.
